

FOURTH SUPPLEMENT DATED 8 APRIL 2022 TO THE PROSPECTUS DATED 30 JUNE 2021, AS SUPPLEMENTED BY THE FIRST SUPPLEMENT DATED 24 AUGUST 2021, THE SECOND SUPPLEMENT DATED 14 DECEMBER 2021 AND THE THIRD SUPPLEMENT DATED 1 MARCH 2022



THE BANK OF NOVA SCOTIA

(a Canadian chartered Bank)

U.S.\$20,000,000,000

Euro Medium Term Note Programme

Due from 1 month to 99 years from the date of original issue

The Bank of Nova Scotia (the “**Issuer**” or the “**Bank**”) issued a prospectus dated 30 June 2021 (as supplemented by the first supplement to such prospectus dated 24 August 2021, the second supplement to such prospectus dated 14 December 2021 and the third supplement to such prospectus dated 1 March 2022) (such prospectus as supplemented, the “**Prospectus**”) which is a base prospectus for the purposes of Article 8 of the UK Prospectus Regulation (as defined below) in respect of notes to be admitted to the Official List of the Financial Conduct Authority and admitted to trading on the Main Market of the London Stock Exchange plc and Admission Particulars in respect of notes to be admitted to trading on the International Securities Market of the London Stock Exchange plc. This fourth supplement (the “**Fourth Supplement**”) constitutes a supplement in respect of the Prospectus for the purposes of Article 23 of the UK Prospectus Regulation and supplementary admission particulars in respect of the Admission Particulars for the purposes of the ISM Rulebook, and is prepared in connection with the U.S.\$20,000,000,000 Euro Medium Term Note Programme established by the Issuer (the “**Programme**”). When used in this Fourth Supplement, “**UK Prospectus Regulation**” means Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.

Terms defined in the Prospectus have the same meaning when used in this fourth Supplement. This Fourth Supplement is supplemental to, and shall be read in conjunction with, the Prospectus and any other supplements to the Prospectus issued by the Issuer from time to time.

The Issuer accepts responsibility for the information contained in this Fourth Supplement. To the best of the knowledge of the Issuer, the information contained in this Fourth Supplement is in accordance with the facts and this Fourth Supplement makes no omission likely to affect its import.

1. Purpose of the Fourth Supplement

The purpose of this Fourth Supplement is to disclose the increase in the Programme Size from U.S.\$20,000,000,000 to U.S.\$30,000,000,000 or the equivalent in other currencies.

2. Increase of Programme Size

By a resolution dated 1 March 2022 of the Board of Directors, the Bank has authorised an aggregate increase in the Programme size to U.S.\$30,000,000,000. References in the Prospectus to the Programme size or the aggregate principal amount of Senior Notes outstanding not exceeding U.S.\$20,000,000,000 or the equivalent in other currencies shall be construed with effect from the date of this Fourth Supplement as if they were references to the Programme size or the aggregate principal amount of Senior Notes outstanding not exceeding U.S.\$30,000,000,000 or the equivalent in other currencies, and references to the “U.S.\$20,000,000,000” or “U.S.\$20,000,000,000 Euro Medium Term Note Programme” shall be to the “U.S.\$30,000,000,000” or “U.S.\$30,000,000,000 Euro Medium Term Note Programme”, in each case effective from the date of this Fourth Supplement.

3. General Information

To the extent that there is any inconsistency between (a) any statement in this Fourth Supplement or any statement incorporated by reference into the Prospectus by way of this Fourth Supplement and (b) any other statement in, or incorporated by reference in, the Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Fourth Supplement, no significant new factor, material mistake or inaccuracy relating to the information included in the Prospectus which is capable of affecting the assessment of Notes issued under the Programme has arisen or been noted, as the case may be, since the approval by the FCA of the third supplement to the Prospectus dated 1 March 2022.

Copies of this Fourth Supplement, the Prospectus and the documents or information incorporated by reference in this Fourth Supplement and the Prospectus can be obtained on written request and without charge from (i) the principal executive offices of the Bank from the Executive Vice-President and General Counsel, The Bank of Nova Scotia, Scotia Plaza, 44 King Street West, Toronto, Ontario M5H 1H1, Canada, Telephone: +1 (416) 866-3672; and (ii) from the offices of the Principal Paying Agent, Registrar, Calculation Agent and Transfer Agent, The Bank of Nova Scotia, London Branch, 201 Bishopsgate, 6th Floor, London EC2M 3NS, United Kingdom; Telephone: +44 (0)20 7638 5644 and may also be viewed free of charge on the website of the Issuer at <https://www.scotiabank.com/ca/en/about/investors-shareholders/funding-programs/euro-medium-term-notes.html> and on the website of the Regulatory News Service operated by the London Stock Exchange plc at <https://www.londonstockexchange.com/exchange/news/market-news/market-news-home.html> under the name of the Issuer.